06:31 AM EDT, 07/22/2025 (MT Newswires) -- AstraZeneca ( AZN ) said it plans to invest $50 billion in the US by 2030, including the development of a new drug substance manufacturing facility in Virginia.

The new Virginia facility is expected to produce small molecules, peptides and oligonucleotides for the UK drugmaker's weight management and metabolic portfolio, including oral glucagon-like peptide-1 and baxdrostat products, it said late Monday. The facility will use artificial intelligence, automation and data analytics to optimize production, according to the company.

AstraZeneca's ( AZN ) US-listed shares inclined 0.7% in Tuesday's most recent premarket activity.

The five-year investment includes the expansion of the firm's research and development facilities in Maryland and Massachusetts, as well as its cell therapy manufacturing facilities in Maryland and California. The plan also includes continuous manufacturing expansion in Indiana and specialty manufacturing expansion in Texas.

The investment supports AstraZeneca's ( AZN ) aim to reach $80 billion in revenue by 2030, with 50% of that total expected to be generated in the US. Currently, the world's largest economy accounts for 42% of the company's overall topline.

"Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally," AstraZeneca ( AZN ) Chief Executive Pascal Soriot said in a statement. "It will also support our ambition to reach $80 billion in revenue by 2030."

AstraZeneca ( AZN ) anticipates creating "tens of thousands" of direct and indirect jobs in the US with its latest investment. In November, the company said it will spend $3.5 billion in the US to expand its research and manufacturing capabilities by the end of 2026.

"We are proud that AstraZeneca ( AZN ) has made the decision to bring substantial pharmaceutical production to our shores," US Secretary of Commerce Howard Lutnick said, according to AstraZeneca's ( AZN ) statement. "This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here."

President Donald Trump reportedly threatened to set tariffs of up to 200% on imports of pharmaceutical products during a Cabinet meeting earlier in July. Trump also suggested in the meeting that he may give drug manufacturers a certain period of time to "get their act together."

"For decades Americans have been reliant on foreign supply of key pharmaceutical products," Lutnick said Monday. "President Trump and our nation's new tariff policies are focused on ending this structural weakness."